Eugenie Kleinerman, MD, Oral History Interview, May 21, 2014
Files
Download Full Interview Transcript (786 KB)
Loading...
Description
Major Topics Covered:
- Personal and educational background
Identifier
KleinermanE_01_05212014
Publication Date
5-21-2014
Publisher
The Historical Resources Center, Research Medical Library, The University of Texas Cancer Center
City
Houston, Texas
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Topics Covered
University of Texas MD Anderson Cancer Center, UT MD Anderson Cancer Center, University of Texas System. M.D. Anderson Cancer Center, M.D. Anderson Hospital and Tumor Institute at Houston, University of Texas M.D. Anderson Cancer Center, M.D. Anderson Hospital and Tumor Institute
Disciplines
History of Science, Technology, and Medicine | Oncology | Oral History
Recommended Citation
Kleinerman, Eugenie S. MD and Rosolowski, Tacey A. PhD, "Eugenie Kleinerman, MD, Oral History Interview, May 21, 2014" (2014). Interview Sessions. 241.
https://openworks.mdanderson.org/mchv_interviewsessions/241
Conditions Governing Access
Redacted
About the Interview
About the Interview Subject:
Dr. Eugenie Kleinerman (b. 16 April 1949, Baltimore, Maryland) was recruited to MD Anderson in 1984 as an Assistant Professor in the Department of Pediatrics. Today she holds the Mary V. and John A. Reilly Distinguished Chair. She also has a joint appointment with the Department of Cancer Biology.
Dr. Kleinerman is best known as a pioneer in the use of immunological treatments for osteosarcoma. Her first discoveries involved the agent, MEPACT, and she has gone on to investigate many agents, combination therapies, and novel delivery systems.
As Head of Pediatrics at MD Anderson, a role she has served since 2001,Dr. Kleinerman established an oncology services specifically designed for pediatric patients, and was successful in establishing their unique identity in the “hospital within a hospital,” the Children’s Cancer Hospital.